Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Martínez, Carmen  [Clear All Filters]
2014
Fehér C, Rovira M, Soriano A, Esteve J, Martínez JAntonio, Marco F, Carreras E, Martínez C, Fernández-Avilés F, Suárez-Lledó M, et al. Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study. J Antimicrob Chemother. 2014.
2019
Gutiérrez-García G, Cibeira MTeresa, Rovira M, de Larrea CFernández, Tovar N, Rodríguez-Lobato LGerardo, Rosiñol L, Marín P, Solano-Vega J, Suárez-Lledó M, et al. Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis. Bone Marrow Transplant. 2019.
Suárez-Lledó M, Marcos MAÁngeles, Cuatrecasas M, Bombi JAntoni, Fernández-Avilés F, Magnano L, Martínez-Cibrián N, Llobet N, Rosiñol L, Gutiérrez-García G, et al. Quantitative PCR is faster, more objective and more reliable than immunohistochemistry for the diagnosis of Cytomegalovirus Gastrointestinal disease in allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2019.
2020
Rodríguez-Lobato L-G, Martínez-Roca A, Castaño-Díez S, Palomino-Mosquera A, Gutiérrez-García G, Pedraza A, Suárez-Lledó M, Rovira M, Martínez C, de Larrea CFernández, et al. The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever. PLoS One. 2020;15(11):e0241778.
Martínez C, Carpio C, Heras I, Ríos-Herranz E, Buch J, Gutierrez A, Romero S, Zeberio I, García-García I, Rodriguez-Izquierdo A, et al. Potential survival benefit for patients receiving allogeneic hematopoietic stem cell transplantation after nivolumab therapy for relapse/refractory Hodgkin lymphoma: Real-life experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation,. Biol Blood Marrow Transplant. 2020.
2022
Salas MQueralt, Charry P, Pedraza A, Martínez-Cibrián N, Solano MTeresa, Domenech A, Suárez-Lledó M, Nomdedeu M, Cid J, Lozano M, et al. PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT. Transplant Cell Ther. 2022.
2023
Ruiz-Boy S, Pedraza A, Prat M, Salas MQueralt, Carcelero E, Riu-Viladoms G, Suárez-Lledó M, Monge-Escartín I, Rodríguez-Lobato LGerardo, Martínez-Roca A, et al. At-Home Foscarnet Administration in Patients with Cytomegalovirus Infection Post-Allogeneic Stem Cell Transplantation: A Unicentric, Safe, and Feasible Program. Pharmaceuticals (Basel). 2023;16(12).
Pedraza A, Salas MQueralt, Rodríguez-Lobato LGerardo, Escribano-Serrat S, Suárez-Lledó M, Martínez-Cebrian N, Solano MTeresa, Arcarons J, Rosiñol L, Gutiérrez-García G, et al. EASIX SCORE CORRELATES WITH ENDOTHELIAL DYSFUNCTION BIOMARKERS AND PREDICTS RISK OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC TRANSPLANTATION. Transplant Cell Ther. 2023.
Penack O, Peczynski C, Boreland W, Lemaitre J, Afanasyeva K, Kornblit B, Jurado M, Martínez C, Natale A, Pérez-Simón JAntonio, et al. ECP versus ruxolitinib in steroid-refractory acute GVHD - a retrospective study by the EBMT transplant complications working party. Front Immunol. 2023;14:1283034.
Salas MQueralt, Pedraza A, Charry P, Suárez-Lledó M, Rodríguez-Lobato LGerardo, Brusosa M, Solano MTeresa, Serrahima A, Nomdedeu M, Cid J, et al. Post-transplant Cyclophosphamide and Tacrolimus for GVHD Prevention Allo-HCT from HLA-Matched Donors Generates more Advantages than Limitations. Transplant Cell Ther. 2023.
Rodríguez-Arbolí E, Lee CJ, Caballero-Velázquez T, Martínez C, García-Calderón C, Jiménez-León MReyes, Bermúdez-Rodríguez MAránzazu, López-Corral L, Triguero A, Onstad L, et al. Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials. Clin Cancer Res. 2023:OF1-OF11.
2024
Penack O, Peczynski C, Boreland W, Lemaitre J, H Reinhardt C, Afanasyeva K, Avenoso D, Holderried TAW, Kornblit BThomas, Gavriilaki E, et al. ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party. Bone Marrow Transplant. 2024.
Castro-Vázquez D, Arribas-Castaño P, García-López I, Gutiérrez-Cañas I, Pérez-García S, Lamana A, Villanueva-Romero R, Cabrera-Martín A, Tecza K, Martínez C, et al. Vasoactive intestinal peptide exerts an osteoinductive effect in human mesenchymal stem cells. Biofactors. 2024.